SML0650
Risedronate sodium
≥97% (HPLC)
Synonym(s):
P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C7H10NO7P2 · Na
CAS Number:
Molecular Weight:
305.09
UNSPSC Code:
41106300
NACRES:
NA.77
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
H2O: 5 mg/mL, clear (warmed)
storage temp.
room temp
SMILES string
[Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
InChI
1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
InChI key
DRFDPXKCEWYIAW-UHFFFAOYSA-M
Biochem/physiol Actions
Risedronate sodium is a bisphosphonate bone resorption inhibitor.
Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Seiji Ohtori et al.
Spine, 38(8), E487-E492 (2013-01-29)
Prospective study. To examine the efficacy of teriparatide or bisphosphonate treatment to reduce pedicle screw (PS) loosening after instrumented lumbar posterolateral fusion in postmenopausal women with osteoporosis. Failure of fixation caused by loosening of PSs in osteoporosis is a problem
Y Sato et al.
Journal of musculoskeletal & neuronal interactions, 13(3), 346-352 (2013-08-31)
Minodronate is a nitrogen-containing bisphosphonate that is commercially available for the treatment of osteoporosis in Japan. Preclinical studies demonstrated that minodronate is at least 10 times more potent than alendronate in inhibiting bone resorption in vivo. A high incidence of
J B Matheny et al.
Bone, 57(1), 277-283 (2013-08-31)
Alterations in resorption cavities and bone remodeling events during anti-resorptive treatment are believed to contribute to reductions in fracture risk. Here, we examine changes in the size of individual remodeling events associated with treatment with a selective estrogen receptor modulator
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML0650-50MG | 04061837101205 |